Stock Scorecard
Stock Summary for Vir Biotechnology Inc (VIR) - $9.62 as of 12/9/2023 2:42:26 AM EST
Total Score
14 out of 29
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for VIR
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for VIR
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for VIR
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for VIR
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for VIR
Financial Details for VIR
Company Overview |
|
---|---|
Ticker | VIR |
Company Name | Vir Biotechnology Inc |
Country | USA |
Description | Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California. |
Sector Name | LIFE SCIENCES |
Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
Most Recent Quarter | 9/30/2023 |
Next Earnings Date | 2/21/2024 |
Stock Price History |
|
Last Day Price | 9.62 |
Last Day Price Updated | 12/9/2023 2:42:26 AM EST |
Last Day Volume | 0 |
Average Daily Volume | N/A |
52-Week High | 31.55 |
52-Week Low | 7.72 |
Last Price to 52 Week Low | 24.61 % |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 158.38 |
Sector PE | 62.37 |
5-Year Average PE | 0.41 |
Free Cash Flow Ratio | 0.76 |
Industry Free Cash Flow Ratio | 17.89 |
Sector Free Cash Flow Ratio | 31.15 |
Current Ratio Most Recent Quarter | 10.72 |
Total Cash Per Share | 12.64 |
Book Value Per Share Most Recent Quarter | 12.45 |
Price to Book Ratio | 0.77 |
Industry Price to Book Ratio | 4.65 |
Sector Price to Book Ratio | 19.59 |
Price to Sales Ratio Twelve Trailing Months | 10.89 |
Industry Price to Sales Ratio Twelve Trailing Months | 16.60 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.61 |
Share Statistics |
|
Total Shares Outstanding | 134,521,000 |
Market Capitalization | 1,294,092,020 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Dividend King? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00 % |
5-Year Dividend Payments Count | 0 |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 58.50 % |
Annual Earnings Growth | -2.41 % |
Reported EPS 12 Trailing Months | -4.50 |
Reported EPS Past Year | -3.73 |
Reported EPS Prior Year | 3.81 |
Net Income Twelve Trailing Months | -600,747,000 |
Net Income Past Year | 515,837,000 |
Net Income Prior Year | 528,584,000 |
Quarterly Revenue Growth YOY | -99.30 % |
5-Year Revenue Growth | 484.51 % |
Balance Sheet |
|
Total Cash Most Recent Quarter | 1,700,000,000 |
Total Cash Past Year | 2,400,000,000 |
Total Cash Prior Year | 909,500,000 |
Net Cash Position Most Recent Quarter | 1,700,000,000 |
Net Cash Position Past Year | 2,400,000,000 |
Long Term Debt Past Year | 0 |
Long Term Debt Prior Year | 0 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | 1.00 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 2,077,963,000 |
Total Stockholder Equity Prior Year | 1,431,849,000 |
Total Stockholder Equity Most Recent Quarter | 1,675,085,000 |
Options |
|
Put/Call Ratio | 0.44 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.16 |
MACD Signal | 0.19 |
20-Day Bollinger Lower Band | 6.53 |
20-Day Bollinger Middle Band | 10.40 |
20-Day Bollinger Upper Band | 14.27 |
Beta | 0.38 |
RSI | 53.38 |
50-Day SMA | 19.43 |
200-Day SMA | 31.67 |
System |
|
Modified | 12/10/2023 1:28:58 AM EST |